{"organizations": [], "uuid": "433ed8330d977b8326de4e701447c266fe0ea81b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-agtc-doses-first-patient-in-phase/brief-agtc-doses-first-patient-in-phase-1-2-clinical-study-of-gene-therapy-for-treatment-of-x-linked-retinitis-pigmentosa-idUSFWN1RV0DQ", "country": "US", "domain_rank": 408, "title": "BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T14:10:00.000+03:00", "replies_count": 0, "uuid": "433ed8330d977b8326de4e701447c266fe0ea81b"}, "author": "", "url": "https://www.reuters.com/article/brief-agtc-doses-first-patient-in-phase/brief-agtc-doses-first-patient-in-phase-1-2-clinical-study-of-gene-therapy-for-treatment-of-x-linked-retinitis-pigmentosa-idUSFWN1RV0DQ", "ord_in_thread": 0, "title": "BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa", "locations": [], "entities": {"persons": [{"name": "stu", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "gene therapy for treatment of x-linked retinitis pigmentosa market news", "sentiment": "negative"}, {"name": "treatment of x-linked retinitis pigmentosa reuters", "sentiment": "none"}, {"name": "applied genetic technologies corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  11 AM / Updated 14 minutes ago BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa Reuters Staff 1 Min Read \nApril 18 (Reuters) - Applied Genetic Technologies Corp : \n* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-18T14:10:00.000+03:00", "crawled": "2018-04-18T14:33:45.012+03:00", "highlightTitle": ""}